Nuvation Bio Inc. 4

Nuvation Bio Inc. CFO Philippe Sauvage exercised options to acquire 40,000 shares of Class A Common Stock, increasing his direct holdings to 54,131 shares.

On July 15, 2026, Nuvation Bio Inc. Chief Financial Officer Philippe Sauvage exercised two stock options, acquiring an aggregate 40,000 shares of Class A Common Stock at exercise prices of $2.17 (39,999 shares) and $1.97 (1 share), and these option exercises were reported as increasing his direct holdings to 54,131 shares. The underlying options, originally for 39,999 and 1 shares with expiration dates of October 6, 2034 and February 27, 2035 respectively, were reduced to zero as they were fully exercised. Based on the current market price of $5.80, the value of the shares acquired is approximately $232,000, while the cost paid via option exercise is about $86,800, implying a gain on exercise but still a modest-sized, compensation-related transaction. After the exercises, Sauvage’s direct common stock holdings, including shares previously acquired via the employee stock purchase plan, are worth roughly $314,000 at the current market price, and there is no indication of any open-market sale associated with this Form 4.

Filing Facts

CIK

1811063

Ticker

NUVB

Form

4

Source Type

fda

Accession

0002039891-26-000008

Alert Tier

5